S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
S-1 is a new chemotherapy drug. Some phase II trials showed S-1 is effective in
Hepatocellular Carcinoma (HCC). S-1 combined with calcium folinate (SL) showed very good
efficiency and safety in colorectal cancer (CRC). The short duration (two weekly regimen) is
better than common course 4 week regimen in tolerance. So the investigators want to examine
the efficiency and safety of SL one week on and one week off regimen in HCC.